Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Myeloid, Chronic-Phase 3Polycythemia Vera 2Neoplasm Metastasis 2Carcinoma, Renal Cell 2Uveal Melanoma 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Primary Myelofibrosis 1Osteosarcoma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplasms 1Metastatic Gastrointestinal Carcinoid Tumor 1Lymphoma, Non-Hodgkin 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia 1Kidney Neoplasms 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Graft vs Host Disease 1Glioma 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1

Interventions

Rituximab 205Cyclophosphamide 178Peripheral Blood Stem Cell Transplantation 93Etoposide 91fludarabine phosphate 86Filgrastim 81Melphalan 62Vincristine 60Mycophenolic Acid 58Busulfan 58Whole-Body Irradiation 57Cytarabine 51Radiotherapy 49Doxorubicin 49Cyclosporine 49Tacrolimus 48Granulocyte Colony-Stimulating Factor 48Prednisone 46fludarabine 45Bendamustine Hydrochloride 45Methotrexate 44Carmustine 36Antilymphocyte Serum 34Dexamethasone 32Bortezomib 29Gemcitabine 27ibritumomab tiuxetan 25Methylprednisolone 23sargramostim 22Stem Cell Transplantation 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Non-Hodgkin × peginterferon alfa-2b × Clear all
NCT00574730 2023-09-14

CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma

University of Nebraska

Phase NA Completed
27 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡